What drug is Asiminib?

Asciminib, also known asAsciminib, is a new type of targeted therapy drug, classified as a tyrosine kinase inhibitor (TKI), and is a third-generation product in this field. This drug is mainly targeted at patients with chronic myeloid leukemia (CML), especially those who are resistant to traditional first- and second-generation TKIs (such as imatinib, dasatinib and nilotinib), providing new treatment hope for these patients.

Aximini has a unique mechanism of action. It mainly acts on the myristoyl binding pocket of the BCR-ABL fusion protein. BCR-ABLfusion protein is a key driver of CML cell proliferation and survival. Unlike early TKI, aximini can specifically inhibit the kinase activity of this protein, thereby effectively controlling the growth of CML cells. Especially in patients with T315I mutation, aceminib has shown excellent efficacy.

Aximini is mainly used for the treatment of chronic myelogenous leukemia. It can be used as a treatment option in patients with chronic and accelerated CML, especially when patients are resistant to traditional TKI therapies. Clinical trial data show that aximini can significantly improve patients' response rate, including cytological response and molecular response, and bring better treatment effects and prognosis to patients.

Aximini is usually given as an oral tablet, and the recommended starting dose is 40mg twice daily. Patients should strictly follow medical instructions and take medications on time to maintain stable blood drug concentrations. At the same time, you should avoid taking the medicine at the same time as high-fat foods to avoid affecting the absorption of the medicine.

Although aceminib is highly effective, patients should also be aware of its potential side effects, such as nausea, diarrhea, fatigue, and headaches when using it. Some patients may develop liver function impairment or hematological abnormalities, so regular monitoring of patients' liver function and blood indicators is crucial.